Literature DB >> 24390366

Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver.

Akinori Okumura1, Hiroyuki Unoki-Kubota, Yumi Matsushita, Tomoko Shiga, Yuriko Moriyoshi, Satoshi Yamagoe, Yasushi Kaburagi.   

Abstract

Leukocyte cell-derived chemotaxin 2 (LECT2) is a signaling molecule expressed in the liver and regulated by Wnt/β-catenin pathways implicated in hepatic metabolism. However, the clinical relevance of LECT2 in obesity and fatty liver is unknown. The objective of this study was to determine whether serum LECT2 levels are affected by of obesity and fatty liver. A cross sectional study comprising 231 Japanese adult subjects were tested for LECT2 using a highly sensitive assay. We evaluated the associations between LECT2 and the anthropometric or clinical markers of obesity and fatty liver. The mean serum LECT2 levels were 43.5 ± 13.6 ng/mL. LECT2 positively correlated with all the anthropometric measures of obesity: body mass index, waist circumference, waist-to-hip ratio, and waist-to-height ratio (W/Ht). Multiple regression analysis revealed that LECT2 is independently related to γ-glutamyl transpeptidase (γ-GTP), triglyceride, and age in males, whereas in females it was related to the homeostasis model assessment ratio, blood urea nitrogen, high-density lipoprotein cholesterol, and γ-GTP. Receiver operating characteristics curve analyses revealed that LECT2 correlated with obesity [area under the curve (AUC) 0.655, 95% confidence interval (CI) = 0.551-0.758, p = 0.002 in males; AUC 0.670, 95% CI = 0.570-0.770, p < 0.001 in females] and fatty liver (AUC 0.646, 95% CI = 0.544-0.749, p = 0.004 in males; AUC 0.733, 95% CI = 0.621-0.844, p < 0.001 in females). The present study indicates that serum LECT2 levels are increased by obesity and fatty liver, and suggests that LECT2 is a novel obesity-related protein.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24390366

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  21 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

2.  Hepatokines: unlocking the multi-organ network in metabolic diseases.

Authors:  Alison Iroz; Jean-Pierre Couty; Catherine Postic
Journal:  Diabetologia       Date:  2015-06-02       Impact factor: 10.122

3.  Will inhibition of cellular crosstalk resolve liver fibrosis?

Authors:  Edward N Harris
Journal:  Hepatology       Date:  2022-03-03       Impact factor: 17.298

4.  Crystal Structure of Human Leukocyte Cell-derived Chemotaxin 2 (LECT2) Reveals a Mechanistic Basis of Functional Evolution in a Mammalian Protein with an M23 Metalloendopeptidase Fold.

Authors:  Hai Zheng; Takuya Miyakawa; Yoriko Sawano; Atsuko Asano; Akinori Okumura; Satoshi Yamagoe; Masaru Tanokura
Journal:  J Biol Chem       Date:  2016-06-22       Impact factor: 5.157

5.  Leukocyte cell derived chemotaxin-2 (Lect2) as a predictor of survival in adult acute liver failure.

Authors:  Voytek Slowik; Prachi Borude; Hartmut Jaeschke; Benjamin L Woolbright; William M Lee; Udayan Apte
Journal:  Transl Gastroenterol Hepatol       Date:  2019-03-20

Review 6.  Implication of hepatokines in metabolic disorders and cardiovascular diseases.

Authors:  Tae Woo Jung; Hye Jin Yoo; Kyung Mook Choi
Journal:  BBA Clin       Date:  2016-03-05

Review 7.  Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets.

Authors:  Feliciano Chanana Paquissi
Journal:  Front Immunol       Date:  2016-11-11       Impact factor: 7.561

Review 8.  Leukocyte Cell-Derived Chemotaxin-2: It's Role in Pathophysiology and Future in Clinical Medicine.

Authors:  V Slowik; U Apte
Journal:  Clin Transl Sci       Date:  2017-05-23       Impact factor: 4.689

9.  Visceral fat area is a strong predictor of leukocyte cell-derived chemotaxin 2, a potential biomarker of dyslipidemia.

Authors:  Kumpei Tanisawa; Hirokazu Taniguchi; Xiaomin Sun; Tomoko Ito; Ryoko Kawakami; Shizuo Sakamoto; Mitsuru Higuchi
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

10.  Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma.

Authors:  Hirohisa Okabe; Evan Delgado; Jung Min Lee; Jing Yang; Hiroki Kinoshita; Hiromitsu Hayashi; Allan Tsung; Jaideep Behari; Toru Beppu; Hideo Baba; Satdarshan P Monga
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.